Bausch + Lomb
BLCO | NYSE
$20.88
-$0.21 (-1.00%)
At close: Nov 16, 2026, 4:00 PM ET
$20.88
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:49 PM ET
Bausch + Lomb Company Profile
Company profile explainedCompany Profile
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Key Executives
| Name | Position |
|---|---|
| Brenton L. Saunders | Chief Executive Officer & Director |
| A. Robert D. Bailey | Executive Vice President & Chief Legal Officer |
| Osama A. Eldessouky | Executive Vice President & Chief Financial Officer |
| Alan Waterhouse CPFA | Executive Vice President and Chief Supply Chain & Operations Officer |
| Andrew Stewart | President of Global Pharmaceuticals & International Consumer |
| Asli Gevgilili | Executive Vice President & Chief Human Resources Officer |
| Crawford | Chief Communications Officer |
| Frederick J. Munsch | Senior Vice President, Controller & Chief Accounting Officer |
| George Gadkowski | Vice President & Head of Investor Relations & Business Insights |
| John Ferris | President of Consumer |
| Jonathon L. Kellerman | Chief Compliance Officer |
| Luc Bonnefoy | President of Surgical |
| Manisha A. Narasimhan | Chief Corporate Development & Digital Officer |
| Yang Yang | President of Vision Care |
| Yehia Hashad | Executive Vice President of Research & Development and Chief Medical officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 8-K | Current Report |
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 13, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 3 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 3 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 3 | Filing |
Bausch + Lomb
| Country | Canada |
| IPO Date | May 6, 2022 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 13,000 |
| CEO | Thomas J. Appio |
Contact Details
520 Applewood Crescent Vaughan,
ON L4K 4B4 Canada
Stock Details
| Ticker Symbol | BLCO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860742 |
| CUSIP Number | 071705107 |
| ISIN Number | CA0717051076 |
| SIC Code | 3851 |
Recent News
- 3 days ago / zacks.comBest Growth Stocks to Buy for November 13th
- 5 days ago / zacks.comBest Growth Stocks to Buy for November 11th
- 8 days ago / zacks.comBest Growth Stocks to Buy for November 9th
- 11 days ago / seekingalpha.comBausch + Lomb: Profits Return In Q3 As A Recovery Story, While Pipeline Grows
- 12 days ago / zacks.comAre You Looking for a Top Momentum Pick? Why Bausch + Lomb (BLCO) is a Great Choice
- 12 days ago / zacks.comMidterm Election Rally: 5 Relative Price Strength Stocks to Buy
- 12 days ago / zacks.comBest Growth Stocks to Buy for November 5th
- 12 days ago / fool.comBausch + Lomb: 3 Key Takeaways for Long-Term Investors
- 13 days ago / zacks.comWhy Bausch + Lomb (BLCO) Might be Well Poised for a Surge
- 13 days ago / zacks.comWhy Bausch + Lomb (BLCO) is a Top Momentum Stock for the Long-Term
Add to Watchlist
Select watchlists to add or remove BLCO